In this study we investigated the immunochemical and cytochemical reactivity of two monoclonal antibodies against the 16-amino acid tandem repeat of MUC4 to demonstrate a possible variation of the mucin core peptide expression related to lung cancer. The immunocytochemical anti-MUC4 reactivity was analyzed in four lung cancer cell lines (Calu-1, Calu-3, H460, SKMES) and in other tumor cell lines, as well as in frozen materials from 21 lung adenocarcinomas (ACs), including five bronchioloalveolar carcinomas (BACs), and 11 squamous cell lung carcinomas (SqCCs). A weak fluorescence anti-MUC4 positivity (range: 10.3-16.2) was observed only in acetone-fixed lung cancer cell lines Calu-1, Calu-3 and H460. These three lung cancer cell lines also showed a cytoplasmic immunoperoxidase reactivity. The immunostaining in lung cancer tissues showed a granular cytoplasmic reactivity: 15/21 (71%) and 17/21 (80%) ACs were positive with BC-LuC18.2 and BC-LuCF12, respectively. All BACs were positive. Moderate to strong reactivity was present in well-differentiated ACs. In the normal lung parenchyma counterparts weak reactivity was found only in bronchiolar cells. All SqCCs were negative. Anti-MUC4 reactivity was also observed in the alveolar mucus. In conclusion, our anti-MUC4 MAbs detect a secretion product present in mucus and this product is elaborated by lung cancer cells and overexpressed in well-differentiated lung ACs. (Int J Biol Markers, 2000; 15: 312-20) 
INTRODUCTION
Mucins are high molecular weight (>200 kDa) Olinked glycoproteins expressed on the apical surface of polarized secretory epithelial tissues; these glycoconjugates represent the major components of mucus, a viscous biofilm which covers most of the respiratory, genitourinary, gastrointestinal and mammary tracts. The protein core moiety (apomucin) of the human mucins has a molecular weight ranging from 40 to 600 kD and consists of repeated amino acid sequences called tandem repeats (TR), which in composition and number are peculiar to each individual mucin. The heterogeneity of mucins of different origin is also due to differences in the nonrepetitive domains. Within the tandem repeats there are multiple serine, threonine and proline residues, which represent the sites of O-glycosylation. The most important O-linked glycans present in the mucins are Nacetylgalactosamine, N-acetylglucosamine, galactose, fucose, and sialic acid (1) . The highly immunogenic carbohydrate chains, which are the main component of mucin (80%) and heavily mask the protein backbone, represent the antigenic target of most of the produced antimucin monoclonal antibodies. So far, cDNA cloning studies have identified 10 apomucin-encoding genes that have been given MUC symbols numbered 1, 2, 3, 4, 5AC, 5B, 6, 7, 8, 9 (1-3) . MUC1 mucin is a membrane-bound molecule preferentially expressed by breast as well as other epithelial tissues (1, 2, 4) ; the secretory mucin family includes all the other mucins, which are expressed in a relatively organspecific manner (1, 3, (5) (6) (7) (8) (9) (10) (11) .
Several studies have reported that the main mucin components of the airway tract are MUC4, MUC5 and MUC8 (2, 7, 8, (12) (13) (14) (15) . The MUC4 gene is located on chromosome 3q29 and shows a polymorphism of the central 48bp VNTR motif (13, 16, 17) . Its apoprotein consists of a tandem repeat made up of 16 amino acids, which are repeated at least 39 times. Little is known about the biology of this mucin. The data available so far indicate that lung and colon cancers preferentially express increased MUC4 mRNA transcripts compared to their normal counterparts (18) (19) (20) (21) (22) (23) (24) . However, the presence of MUC4 has also been demonstrated in other normal tissues, such as the uterine endocervix and the stratified conjunctival epithelium (25, 26) . MUC4 mRNA species have not been detected in normal pancreas, gallbladder, stomach and breast tissues, but their occurrence has been described in tumor tissues/cell lines derived from some of these organs, suggesting that MUC4 might play an important, albeit undefined, role in tumor biology (27) (28) (29) (30) . As regards the human lung tissue, MUC4 expression has been detected in the second-trimester fetal trachea and the majority of cells of the large airway epithelium, whereas in the normal adult its expression has been described in goblet and ciliated cells and acinar glands of the trachea and bronchi (23, 31, 32) . MUC4 mRNA has also been detected in the border epithelium of the inferior turbinates (33) .
One of the main characteristics of cancer-associated mucin products is that they are overexpressed and aberrantly glycosylated in carcinomas and can be abundantly secreted by tumor cells into the circulation of patients (34) (35) (36) (37) (38) . These oligosaccharides can be detected in patient sera by monoclonal antibodies (34, (38) (39) (40) . Moreover, since mucins are characterized by a relative tissue specificity depending on the preferential expression of the encoding gene (1, 2) , increased blood concentrations of a certain mucin are associated with a particular epithelial tumor and can be a useful circulating indicator for differential in vitro cancer diagnosis and monitoring. Examples of such tumor markers are CA 15.3, MCA, CA459, MAM6, CASA and Truquant BR (all products of the MUC1 gene) for breast carcinomas, CA 125 for ovarian carcinoma, CA 19.9 and TAG 72.4 for colorectal and pancreatic carcinomas, while other mucins, such as CA50, are pancarcinoma markers. As mentioned above, MUC4 is the major mucinous component of the respiratory tract epithelium and might thus be a marker for lung cancer; however, its presence in the blood of cancer patients has never been investigated.
The typical incomplete mucin glycosylation occurring in cancer cells can unmask the mucin core peptide sequences of the apoprotein which, consequently, would become more readily detectable by the antibodies. In this context, since little is known about the expression of the mucin core peptide in normal or cancer cells, we have sought to produce monoclonal antibodies that define the tandem repeat of MUC4, the "tile peptide" of the mucin apoprotein, to demonstrate possible variations in mucin protein core expression related to lung cancer. Our monoclonal antibodies recognize an antigen that is overexpressed in lung cancer cells and released into both alveolar and neoplastic glandular luminal mucous secretions.
MATERIAL AND METHODS

Structure of the immunogen and immunization
A synthetic 16-amino acid peptide, whose sequence corresponded to that of the MUC4 core tandem repeat, was used as immunogen. In an effort to enhance the immunogenic potential of this small 16-aa peptide, a peculiar approach to antipeptide antibody elicitation was pursued, based on the use of a small immunogenically inert core molecule of radially branching lysine dendrites (Lysin 4 MAP-tree) to which the peptide had been chemically linked (Fig. 1 ). The resulting macromolecule has a unique three-dimensional configuration in which the peptide is multiexpressed and thus able to elicit an antibody response.
Three Balb/c mice received one intraperitoneal (i.p.) injection of 10 mg of pure synthetic immunogen (solubilized in PBS) with complete Freund's adjuvant, followed at seven-day intervals by another four i.p. injections of the same immunizing material with incomplete Freund's adjuvant. Three days before sacrifice the animal having the highest specific antibody titer against the immunogen peptide (demonstrated by an ELISA test, see below) received daily i.p. injections of 10 mg of peptide without the adjuvant.
Production and screening of anti-MUC4 monoclonal antibodies
The spleen cells of the immunized mouse were fused with NS0 myeloma cells. After somatic hybridization, the obtained hybridomas were grown in a selective medium consisting of RPMI-1640 containing HAT1x, 20% fetal serum CPSR-3 (γ-globulin-deprived) and 1% L-glutamine, sodium-pyruvate, non-essential amino acids, and penicillin/streptomycin (all products supplied by Sigma, Italy). The specific reactivity of the hybridoma supernatants was then screened using a particular ELISA test based on avidin-biotin technology. Briefly, 5 µg of avidin (Avidin DX, Vector, USA) solubilized in NaCl 0.15M + NaHCO 3 0.05M pH 8.5, was coated to the wells of a plate (Nunc-immunoplate Maxisorp, Mascia Brunelli, Italy) overnight at 4°C. The following day, after removal of the unbound avidin and saturation with BSA 10% in PBS for 90 min at 37°C, the wells were incubated with 5 µg/well of 95% purity biotinylated MUC4 peptide (synthesized by Neosystem Laboratoires, France) for 30 min at room temperature. Then the unbound biotinylated MUC4 was removed by 3-5 washings with PBS + Tween20 0.02% and 50 µL of the hybridoma supernatants (or sera of the immunized mice) was added to the wells and incubated at 37°C for 45 min. After 3-5 washings with PBS + Tween20 0.02%, 50 µL/well of horseradish peroxidase-conjugate antimouse IgG goat antibody, diluted 1:1000 in PBS containing FCS 20%, was incubated for 1 hr at room temperature; then the unbound antibody was washed off with PBS + Tween 0.02% and finally 50 µL/well of substrate and chromogen solution (1 mg of O-phenyldiamine chlorohydrate solubilized in 15 mL citrate buffer 0.05M pH 5.2 containing H 2 O 2 0.02%) was dispensed and the samples' absorbance values were measured at 492 nm. Supernatants with an optical density >0.1 were considered positive. The hybridomas producing the specific immunoglobulins were then stabilized using a growth medium containing HT1x.
Immunoglobulin isotyping was determined using a specific murine monoclonal antibody commercial kit (Isostrip Mouse Monoclonal Antibody Isotyping Kit, supplied by Boehringer Mannheim, Italy).
The MAbs were purified from cell-free hybridoma supernatants by means of immunoaffinity chromatography (Protein G Sepharose 4 Fast Flow, Pharmacia Biotech, Italy). Briefly, the resin was equilibrated with a two-column bed of starting buffer (NaH 2 PO 4 20 mM, pH 7.0) and then the supernatants were loaded onto the column.
The column was washed with 200-300 mL of starting buffer and subsequently the resin-bound antibody was eluted using glycine buffer 0.1M pH 2.7 and collected in 2.0 mL fractions containing 1/10 volume of neutralizing buffer (Tris-HCl 1M, pH 9.0). The single fractions were spectrophotometrically measured at 280 nm and those containing the eluted antibody were pooled. Lastly, the purified antibody was dialyzed overnight at 4°C with 2 L of saline solution using pore membranes with a molecular cutoff of 12-14 kDa (Millipore, Italy). The purity of the dalyzed antibodies was evaluated by SDS-PAGE with or without ß-mercaptoethanol and the persistence of their functionality was checked by means of the ELISA test described above. The purified antibodies were stored in 1 mL aliquots at -20°C until use.
Tumor cell lines and immunofluorescence flow-cytometry analysis
The lung cancer (Calu-1, Calu-3, H460, SKMES), breast cancer (MCF7, SKBR3, MDA361, DU4475), vulvar epidermoid carcinoma (A431), melanoma (Mewo), colon cancer (HT29) and myeloma (Jurkat) cell lines were grown at 37°C in 5% CO 2 humified atmosphere using 75 cm 2 flasks containing RPMI-1640 supplemented with 5% fetal bovine serum (FBS) and 1% penicillin/ streptomycin, L-glutamine, sodium-pyruvate and non-essential amino acids (Sigma, Italy).
Flow cytometry analysis was either performed on live cells (Mewo, MDA361, SKBR3, Calu-3, DU4475, A431, H460, MCF7, HT29, SKMES, Calu-1) or on cells fixed under different conditions (Table I) . All fixed cells were pretreated for 15 min with Triton 0.1% solubilized in PBS at 0°C. 5x10 5 cells were incubated for 45 min with 20 µg/mL of purified antibody diluted in PBS + BSA 1% solution at 37°C (the negative controls were treated only with this solution in the absence of the antibody) and after three washings with cold PBS containing BSA 1% and Triton 0.01%, FITC-conjugate anti-7S goat immunoglobulins diluted 1:1000 in PBS + BSA 1% were added to the cells and incubated in ice for 30 min. After extensive washings with PBS + Triton 0.01% the cells were resuspended in saline and examined using a FACScan flow cytometer (Becton Dickinson, USA). The cell-bound fluorescence was determined by counting 5000 cells for each sample. The fluorescence peak of the negative controls was set at a log value inferior to 10, and thus samples with fluorescence peak values of >10 were considered positive.
Immunocytochemical staining of frozen tissue specimens and cancer cell lines By examining the data files of the Pathology Division of the Istituto Nazionale per lo Studio e la Cura dei Tumori of Milan, 21 consecutive cases of lung adenocarcinoma (AC), including five cases of bronchioloalveolar carcinoma (BAC), and 11 consecutive cases of squamous cell lung carcinoma (SqCC), of which frozen material was available, were retrieved. This material was collected during the period 1996-1997. The sections of cryopreserved material were stained with hematoxylin and eosin and the neoplasia present in the specimens was reclassified by updated criteria (41) . In three cases of AC and in two cases of SqCC frozen material from the nonneoplastic lung parenchyma was also available. In addition, Calu-1, Calu-3 and H460 lung carcinoma cell lines were tested. The cell lines were diluted in PBS up to a concentration of 10 5 /100 µL and then cytospinned at 500 rpm for 5 min. The slides were left to dry overnight at room temperature. The cryostatic sections were placed on slides pretreated with polylysine and heated for three hours at 60°C or left to dry overnight at room temperature. To avoid background staining a special treatment was applied to both cryostatic sections and cell lines. Briefly, they were fixed with formalin 10% for 10 min at room temperature. After three washings with PBS 0.05M at pH 7.4 the endogenous peroxidase activity was inhibited by incubation for 1 hr at room temperature in the dark with a solution composed of H 2 O 2 0.3% in PBS 0.05M. Subsequently, three washings with PBS + Triton 0.1% were performed, and goat serum (Dako, Denmark) diluted 1:20 in a solution containing BSA 10% + PBS 0.05M + NaN 3 0.1% was applied for 30 min at room temperature. The specimens were then incubated overnight at 4°C with the two MAbs BC-LuC18.2 and BC-LuCF12 (concentration: 20 µg/mL in PBS 0.05M containing BSA 10% and NaN 3 0.1%). The next day the sections were washed with PBS 0.05M and incubated for 30 min with antimouse biotinylated antibody diluted 1:200 in a solution of PBS + BSA 10% + NaN 3 0.1%. The unbound antibody was removed by three washings with PBS + Triton 0.1% and then incubation with peroxidase-conjugated streptavidin (Dako, Denmark) diluted 1:600 in PBS was performed for 30 min. Finally, the reaction was displayed using a solution of acetate buffer 0.05M pH 5.3 containing 40 µg of aminoethylcarbazole (Sigma, Italy) solubilized in 6 mL of dimethylformamide (Fluka, Italy) and 50 µL of
In addition, the specificity was tested by using a mixture of each MAb at a concentration of 20 µg/mL plus the MUC4 peptide at a concentration of 150 µg/mL instead of the MAb alone.
Immunoreactivity was scored as follows: 0 (no or only few scattered stained cells); 1 (up to 10% stained cells); 2 (11-50% stained cells); 3 (51-75% stained cells); 4 (more than 75% stained cells). The intensity of staining was scored as weak, moderate or strong. The site of occurrence of reactivity in the cell was classified as diffuse cytoplasmic, apical or basal. The presence of reactivity in mucinous alveolar material was also evaluated. 
RESULTS
Anti-MUC4 antibodies
Of the three immunized mice only one showed a high antibody titer, and this animal was used for somatic hybridization. Among the almost 150 screened hybridomas, three were reactive with the MUC4 peptide (BC-LuC 18.2, BC-LuCF12 and BC-LuC D1) by indirect binding on microwells coated with the peptide, and the two 
Legend: 0 = no reactive cells; 1+ = up to 10% reactive cells; 2+ = 11-50% reactive cells; 3+ = 51-75% reactive cells; 4+ = more than 75% reactive cells 
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C with high antibody production were further characterized. Isotyping analysis showed that the two monoclonal antibodies BC-LuC18.2 and BC-LuCF12 belong to the IgG 1 subclass (k chains).
Reactivity of the anti-MUC4 antibodies with cancer cell lines
Immunofluorescence assay with the two monoclonal antibodies BC-LuC18.2 and BC-LuCF12 on live cell lines or cell lines fixed with methanol or paraformaldehyde revealed no reactivity of the two reagents (data not shown). By contrast, after fixation with acetone Calu-1, Calu-3 and H460 lung cancer cell lines showed a weak positivity compared to controls (Fig. 2) , whereas no reactivity was observed in the other cell lines tested (Mewo, Jurkat and MCF7) except for HT29, which proved to be weakly positive with BC-LuCF12 (Table  II) . In keeping with these results, the three lung cancer cell lines Calu-1, Calu-3 and H460 cytospun and analyzed by immunoperoxidase showed a cytoplasmic granular reactivity with the two anti-MUC4 antibodies (Fig. 3A-C) .
Reactivity of anti-MUC4 antibodies in lung cancer
The immunohistochemical results in ACs and SqCCs are summarized in Table III . The reactivity was always granular. BC-LuC18.2 was reactive in 15/21 (71%) and BC-LuCF12 in 17/21 (80%) ACs. The BC-LuCF12 antibody showed a more intense reaction in all cases but one. All BACs were reactive, in 3/5 cases with a percentage of stained cells exceeding 50%. The immunoreactivity was diffuse cytoplasmic, with a higher apical intensity in one and a higher basal intensity in two cases ( Figure  4-A-B ). All grade 1 ACs were moderately to strongly reactive, whereas nearly all grade 2 and 3 ACs were nega- tive or showed only weak reactivity in up to 10% of cells. All SqCCs were negative with both MAbs. Reactivity was found also in mucinous material in four cases of BAC (strong in one case), in two cases of grade 1 AC (strong in two cases), in three cases of grade 2 AC (strong in one case) and in two cases of SqCC (Fig. 5 ). In the normal lung parenchyma surrounding the tumor and in the non-neoplastic specimens weak reactivity was found in bronchiolar cells, but the alveolar pneumocytes were negative (Fig. 6 ). The addition of the peptide to each MAb abolished the positive results.
DISCUSSION
Immunofluorescence analysis revealed that the two anti-MUC4 antibodies were unreactive in all live cells, whereas weak positivity was observed only after fixation with acetone and detergent treatment in all three tested lung cancer cell lines (Calu-1, Calu-3, H460) and in the colon cancer cell line (HT29); these data indicate that the cell-associated epitope is present in the cytoplasm and might be masked by the sugar chains of the mucin. This hypothesis is supported by the appearance of reactivity only in cells fixed with acetone (and not in those treated with methanol or paraformaldehyde), perhaps because this treatment results in better exposure of the core peptide by inducing a change in the spatial configuration of the whole molecule. The cytoplasmic location of the antigen is also demonstrated by the observed granular cytoplasmic immunostaining of the two anti-MUC4 antibodies in the same lung cancer cell lines. The masking of the core epitope by the carbohydrate side chains of the mucin is particularly evident in the experiment of Xing et al, who obtained significant enhancement of the immunofluorescence reactivity of anti-MUC4 peptide antibodies in lung cancer cells (Calu-1, Ben, Colo338) and in the colon cancer cell line LS174T after treatment of cells with a deglycosylating agent (42) .
Immunocytochemical analysis of tumor tissue showed an anti-MUC4 cytoplasmic reactivity related to the tumor histotype. The two MAbs BC-LuC18.2 and BC-LuCF12 reacted with 71% and 80% of the tested lung ACs, respectively; in particular all BACs were reactive, with a high percentage of positive cells. By contrast, all SqCCs were unreactive. The anti-MUC4 reactivity proved to be correlated also with tumor grade, being prevalent in well-differentiated BACs and ACs compared to moderately and poorly differentiated tumors. Our immunocytochemical results therefore confirm that mucins are differentiation markers for lung cancer, in agreement with other reports (19, 20, 43) . The reactivity of the two anti-MUC4 antibodies in mucus indicates that these immunoreagents recognize a product that is secreted into the glandular lumen.
The immunocytochemical reactivity of our anti-MUC4 MAbs is consistent with that reported by Xing and coworkers (42) in lung adenocarcinomas, but differs in the SqCC histotype and in the Calu-1 and MCF7 cell lines. In fact, these authors have produced monoclonal antibodies against the whole sequence of a MUC4 VNTR (with some extension into the next VNTR), which were reactive with 86% of lung SqCCs; also antibodies against other mucins, in particular MUC1, have been reported to be uniformly reactive with squamous cell tumors (44) . The different reactivity of our anti-MUC4 antibodies in SqCC carcinomas and in the two cancer cell lines could either be related to the different amino acid sequence of the defined epitope or to the different treatments of tissues/cells used in immunophenotyping. Unlike these authors we observed a weak anti-MUC4 positivity also in normal bronchiolar epithelium. The immunoreactivity of the two anti-MUC4 antibodies in lung cancer lesions and in the normal adjacent tissues confirms our previous report in which we demonstrated increased MUC4 mRNA levels in lung adenocarcinoma tissues compared to the normal counterparts (18) .
In conclusion, our data suggest that the antigen identified by the two anti-MUC4 reagents is a secretion component of normal and neoplastic lung tissue. In lung tumors the antigen is preferentially overexpressed in the well-differentiated ACs and in BACs and it is also detectable in mucus. Further studies are ongoing to define the biochemical characteristics and to develop an immunometric assay for the identification of the antigen in the sera of normal subjects and cancer patients.
